// App-Quantinova.ai

EP1086 : A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)

Researchers

Presenter

  • David Ross

Principal Investigators

  • Tara Cochrane

  • Steven Lane

  • Stephen Larsen

  • Aaron Gerds

  • Anna Halpern

  • Jake Shortt

  • James Rossetti

  • Amber Jones

  • Jennifer Peppe

  • Georges Natsoulis

  • William Stevenson

  • Nicola Vianetti

  • Claire Harrison

  • Hugh Rienhoff

Medical Centers

  • Cancer Program,University of Queensland,Brisbane,Australia

  • Policlinico S.Orsola-Malpighi,Universitaria di Bologna,Bologna,Italy

  • Institute of Academic Surgery, Royal Prince Alfred Hospital, Camperdown, Australia

  • Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, New South Wales, Australia

  • Gold Coast Hospital and Health Service, Gold Coast, Australia

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA

  • Department of Clinical Haematology,Guy's &amp

  • Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia

  • Department of Global Health, University of Washington, Seattle, WA, United States

  • Taussig Cancer Institute,Cleveland Clinic,Cleveland,Vereinigte Staaten

  • Imago BioSciences, Inc.,South San Francisco,United States

  • Department of Rheumatology, Monash Medical Centre, Melbourne, Australia

Locations

  • Australia

  • Italy

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Essential thrombocythemia

Biomarkers

  • Lysine-specific histone demethylase 1A

  • White Blood Cell

Drug/Treatment

  • Anagrelide hydrochloride

  • Interferon

  • Busulfan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03136185

  • NCT04254978

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved